A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart

Journal of Cardiovascular Pharmacology
Lin WuHeather Fraser

Abstract

The benefits of inhibition of fatty acid oxidation (FOX) and stimulation of glucose oxidation (GOX) in ischemia are controversial. The objective of this study was to evaluate the effect of the FOX inhibitor CVT-4325 on the rates of FOX, GOX, myocardial oxygen consumption (MVO2), and cardiac efficiency in the absence and presence of palmitate during demand-induced ischemia of the rodent isolated hearts. Palmitate concentration-dependently increased FOX, decreased GOX, and increased MVO2. CVT-4325 inhibited FOX and increased GOX in the presence (but not the absence) of 1.2 mM palmitate, with EC50 values of 0.9 and 5.8 microM, respectively. The potency for CVT-4325 to inhibit FOX was 10-fold greater (0.9 versus 9.7 microM) in the presence of 1.2 mM compared with 0.4 mM palmitate. The increase in MVO2 caused by 1.2 mM palmitate was significantly reduced by 3 to 10 microM CVT-4325 in guinea pig hearts. In the presence of 1.2 mM palmitate, an increase in pacing rate of the guinea pig heart from 3.5 to 6.5 Hz caused a significant 50% increase in MVO2, a decrease in cardiac efficiency, and an increase in lactate concentration in the cardiac effluent from 0.04 +/- 0.01 to 0.10 +/- 0.02 mM (P < 0.01). CVT-4325 (3 microM) attenuated the i...Continue Reading

References

Jan 1, 1995·Journal of Molecular and Cellular Cardiology·B RodriguesJ H McNeill
Nov 1, 1993·European Heart Journal·S L Chierchia, G Fragasso
Feb 1, 1997·Metabolism: Clinical and Experimental·W C StanleyL F Whitesell
Dec 21, 2000·American Journal of Physiology. Heart and Circulatory Physiology·L WuJ C Shryock
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·William C Stanley
Nov 18, 2004·Bioorganic & Medicinal Chemistry Letters·Elfatih ElzeinJeff A Zablocki
Feb 24, 2005·Current Pharmaceutical Design·Alain Grynberg
Jun 28, 2005·Annals of Vascular Surgery·John B Seal, Bruce L Gewertz
Jul 1, 2005·Physiological Reviews·William C StanleyGary D Lopaschuk
Aug 16, 2005·American Journal of Physiology. Heart and Circulatory Physiology·William C StanleyGary D Lopaschuk
Dec 13, 2005·Coronary Artery Disease·Giuseppe M C RosanoMassimo Fini
Apr 4, 2006·Heart Failure Reviews·William C Stanley, Hani N Sabbah
Aug 29, 2006·Advances in Cardiology·Ariel Diaz, Jean-Claude Tardif

❮ Previous
Next ❯

Citations

Oct 17, 2012·International Journal of Obesity : Journal of the International Association for the Study of Obesity·O J RiderS Neubauer
Jul 29, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Lufang ZhouWilliam C Stanley
Jan 15, 2014·Journal of Cardiac Failure·José Luis WinterSergio Lavandero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.